An Open-label Long-term Safety Study of Buntanetap in Participants With AD

Sponsor
Annovis Bio Inc.
Study ID
NCT07757204
Phase
PHASE2/PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Alzheimer's Dementia (AD)

Eligibility Criteria

Sex
ALL
Age
55 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study will examine the long-term safety of buntanetap in participants with AD who have participated in a prior study of buntanetap in AD.

Key Dates

First listed
Aug 11, 2026
Start date
Sep 21, 2026
Status verified
Jul 2026
Primary completion
Feb 21, 2030
Completion
May 31, 2030

Study Design

Enrollment
400 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single Arm
    All participants receive buntanetap 30 mg qd

Primary Outcome Measure

Safety of buntanetap [ Time Frame: 24 months of treatment ]

Central Contacts

Related Studies